# TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

> **NCT06485466** · PHASE3 · RECRUITING · sponsor: **Guohui Xu** · enrollment: 101 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma
- Transarterial Chemoembolization
- Camrelizumab
- Apatinib

## Interventions

- **COMBINATION_PRODUCT:** TACE plus camrelizumab and apatinib
- **COMBINATION_PRODUCT:** Camrelizumab and apatinib

## Key facts

- **NCT ID:** NCT06485466
- **Lead sponsor:** Guohui Xu
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-10
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485466, "TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06485466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*